Analysts predict that Crispr Therapeutics AG (NASDAQ:CRSP) will report $59.43 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Crispr Therapeutics’ earnings, with the highest sales estimate coming in at $76.70 million and the lowest estimate coming in at $14.30 million. Crispr Therapeutics posted sales of $120,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 49,425%. The company is scheduled to issue its next earnings results on Monday, February 24th.
According to Zacks, analysts expect that Crispr Therapeutics will report full-year sales of $272.00 million for the current fiscal year, with estimates ranging from $226.90 million to $289.27 million. For the next financial year, analysts expect that the company will post sales of $30.04 million, with estimates ranging from $2.03 million to $58.10 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.
Several brokerages have recently weighed in on CRSP. Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 target price on shares of Crispr Therapeutics in a research note on Monday, December 23rd. Chardan Capital reaffirmed a “buy” rating and set a $72.50 target price on shares of Crispr Therapeutics in a research note on Monday, November 18th. Zacks Investment Research downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Goldman Sachs Group upped their target price on Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 19th. Finally, ValuEngine downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 3rd. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have assigned a buy rating to the company. Crispr Therapeutics currently has a consensus rating of “Buy” and an average target price of $71.38.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the completion of the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $390,000. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, President Rodger Novak sold 33,618 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Over the last three months, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of the business. Webster Bank N. A. acquired a new stake in shares of Crispr Therapeutics in the 4th quarter worth $26,000. Perigon Wealth Management LLC acquired a new stake in shares of Crispr Therapeutics in the 4th quarter worth $278,000. Farmers & Merchants Trust Co of Chambersburg PA acquired a new stake in shares of Crispr Therapeutics in the 4th quarter worth $26,000. Millennium Management LLC acquired a new stake in shares of Crispr Therapeutics in the 3rd quarter worth $4,366,000. Finally, Orbimed Advisors LLC acquired a new stake in shares of Crispr Therapeutics in the 3rd quarter worth $21,167,000. 49.82% of the stock is owned by institutional investors and hedge funds.
Shares of CRSP stock opened at $58.33 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The company has a market cap of $3.29 billion, a price-to-earnings ratio of -16.96 and a beta of 3.20. The stock has a 50 day simple moving average of $65.14 and a 200-day simple moving average of $52.14. Crispr Therapeutics has a 1-year low of $29.34 and a 1-year high of $74.00.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: How interest rates affect municipal bond prices
Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
